Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation
- Status
- UNKNOWN
- Phase
- N/A
Integrated Basic Science Within the Instructional Design of Pattern Recognition Training
- Status
- COMPLETED
- Phase
- NA
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- Status
- RECRUITING
- Phase
- PHASE1
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
iToBoS: Clinical Data Acquisition Study
- Status
- UNKNOWN
- Phase
- NA
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Biomarker-driven Therapy for Melanoma
- Status
- COMPLETED
- Phase
- NA
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
- Status
- UNKNOWN
- Phase
- NA
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
- Status
- TERMINATED
- Phase
- N/A
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients
- Status
- COMPLETED
- Phase
- NA
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- Status
- RECRUITING
- Phase
- NA